88 Atheromatous fragments large enough to cause downstream occlusions and parenchymal damage have been shown to be released in ex vivo studies of renal artery stenting.89 Subsequently interest has developed in use of EPD during interventional procedures. Use of complete EPD predictably collects more debris than partial EPD but does not relate to improved renal function between the groups.90 Prospective data come from a

series of 63 patients with baseline CKD. Here the use of EPD resulted in excellent outcomes based on renal function at 6 months post procedure, with improvement in function seen more often in those for whom debris was captured (20 vs 5, P = 0.01).91 This result was not reproduced in a AZD5363 chemical structure randomized trial that compared stenting, stenting with EPD, stenting with glycoprotein IIb/IIIa inhibition (adciximab) and stenting with EPD and adciximab.92 Here, use of EPD did not lead to improved eGFR at 1 month, and indeed was associated buy Talazoparib with a loss of function. The same held true for the use of adciximab in conjunction with stenting. However, in the group where adciximab and EPD were used in conjunction, eGFR showed improvement, not decline (P ≤ 0.05).

This group did have worse renal function to start, eGFR 52 mL/min versus 60 mL/min, and there were more major bleeding episodes than in the other groups. One explanation for these results is that small and Sitaxentan larger size emboli are released during angioplasty93 the larger emboli would be halted by the EPD but not affected

by adciximab whereas smaller emboli could freely pass through the EPD but would be inhibited by glycoprotein IIb/IIIa inhibition. The CORAL trial94 has used EPD in a small proportion of patients, and it may shed further light on its potential benefit. Despite a landmark RCT, many questions still remain regarding the best choices for managing ARVD patients. Basic management regarding lifestyle and standard pharmacotherapy decisions is well engrained, but debate continues over the role of renal revascularization in specific scenarios. While ASTRAL categorically tells us that a ‘one-size fits all’ approach is not correct, the technical differences of CORAL and subgroup analyses from ASTRAL will offer further information. Further advances in patient selection may be provided by the promising MR imaging portfolio, and possibly with investigation of biomarkers, while the use of VEGF may provide novel avenues for treatment. “
“Whilst increasing numbers of elderly people in Australia are commencing dialysis, few Indigenous patients are aged ≥65 years and their outcomes are unknown. We compared the long-term survival, mortality hazards and causes of death between elderly Indigenous and elderly non-Indigenous dialysis patients.